Cannara Biotech announces extension of BMO credit facility, debenture
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2025
0mins
Should l Buy ?
Credit Agreement Extension: Cannara Biotech has amended its credit agreement with the Bank of Montreal, extending the maturity date to December 31, 2027, and consolidating its debt structure to enhance financial flexibility and support long-term strategy execution.
Convertible Debenture Amendments: The terms of Cannara's convertible debenture have been modified to extend its maturity to March 31, 2028, allowing Olymbec Investments to demand partial repayments, while a new convertible debenture is expected to be issued to Javaa Private Equity by September 29, 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
